This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

ONLINE REGISTRATION CLOSES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Yiming Yin, Ph.D.
Postdoctoral Research Fellow at Boston Children's Hospital
Speaker

Profile

Dr. Yiming Yin received her undergraduate degree from Tsinghua University and her Ph.D. from Scripps Research Institute, where she developed a novel approach for in vitro mammalian display of antibodies and biologics. Her post-doctoral studies in the laboratory of Michael Farzan at Boston Children’s Hospital and Harvard Medical School have focused on engineering and in vivo development of primary B cells. This work led to the development of a process for scarlessly replacing mouse and macaque antibody heavy- and light chain genes with those expressing human antibodies. This process uniquely preserves the ability of these cells to affinity mature in vivo. She is now pursuing the clinical and scientific uses of in vivo affinity maturation. These include the development of broader, more potent, and more bioavailable antibodies, generation of new vaccine models, scientific study of B cell maturation, and exploration of the clinical uses of engineered B cells, including those against HIV-1.

Agenda Sessions

  • In Vivo Affinity Maturation of Human Antibodies in Mice

    2:45pm